Down Syndrome and COVID-19: A Perfect Storm?

Cell Reports Medicine 1, 100019

DOI: 10.1016/j.xcrm.2020.100019

Citation Report

#	Article	IF	Citations
1	Clinical characteristics of individuals with Down syndrome deceased with CoVIDâ€19 in Italyâ€"A case series. American Journal of Medical Genetics, Part A, 2020, 182, 2964-2970.	0.7	17
2	The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies—reply. Internal and Emergency Medicine, 2020, 15, 1583-1584.	1.0	21
3	JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Reports, 2020, 33, 108407.	2.9	23
4	Lessons from individuals with Down syndrome during COVID-19. Lancet Neurology, The, 2020, 19, 974-975.	4.9	5
5	Interleukin-6 in Rheumatoid Arthritis. International Journal of Molecular Sciences, 2020, 21, 5238.	1.8	101
6	A Multicentered Study on Epidemiologic and Clinical Characteristics of 37 Neonates With Community-acquired COVID-19. Pediatric Infectious Disease Journal, 2020, 39, e297-e302.	1.1	33
7	COVID-19 and children with Down syndrome: is there any real reason to worry? Two case reports with severe course. BMC Pediatrics, 2020, 20, 561.	0.7	23
8	Mental Health Status of Psychogeriatric Patients During the 2019 New Coronavirus Disease (COVID-19) Pandemic and Effects on Caregiver Burden. Frontiers in Psychiatry, 2020, 11, 578672.	1.3	24
9	Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?. Cytokine and Growth Factor Reviews, 2021, 58, 102-110.	3.2	73
10	COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults. Annals of Internal Medicine, 2021, 174, 572-576.	2.0	145
11	Down's syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach. Neurological Sciences, 2021, 42, 407-413.	0.9	11
12	Trisomy 21 and Coronavirus Disease 2019 in Pediatric Patients. Journal of Pediatrics, 2021, 228, 294-296.	0.9	18
13	Physical activity as a counteracting measure to mitigate the harmful effects of COVID-19 lockdowns: Special focus on healthy children, adolescents, adults, elderly, athletes, and people with Down syndrome., 2021,, 215-234.		1
14	Autoimmunity and Genetic Syndromes: A Focus on Down Syndrome. Genes, 2021, 12, 268.	1.0	20
15	Medical vulnerability of individuals with Down syndrome to severe COVID-19–data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine, 2021, 33, 100769.	3.2	73
16	Specific Susceptibility to COVID-19 in Adults with Down Syndrome. NeuroMolecular Medicine, 2021, 23, 561-571.	1.8	30
17	Opportunities, barriers, and recommendations in Down syndrome research. Translational Science of Rare Diseases, 2021, 5, 99-129.	1.6	33
18	Prenatal histological, cellular, and molecular anomalies in <scp>trisomy</scp> 21 lung. Journal of Pathology, 2021, 255, 41-51.	2.1	10

#	Article	IF	Citations
20	Analysis of the intracellular traffic of IgG in the context of Down syndrome (trisomy 21). Scientific Reports, 2021, 11, 10981.	1.6	5
21	Virtual Interprofessional Learning Due to COVID-19. Journal of Nursing Education, 2021, 60, 346-351.	0.4	4
22	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. Frontiers in Immunology, 2021, 12, 621440.	2.2	26
23	Risk Factors Associated With COVID-19 Outcomes Among People With Intellectual and Developmental Disabilities Receiving Residential Services. JAMA Network Open, 2021, 4, e2112862.	2.8	26
25	The unfolding palette of COVID-19 multisystemic syndrome and its neurological manifestations. Brain, Behavior, & Immunity - Health, 2021, 14, 100251.	1.3	22
26	Cerebral venous thrombosis in a patient with Down syndrome and coronavirus disease 2019: a case report. Journal of Medical Case Reports, 2021, 15, 364.	0.4	2
27	A SÃndrome de Down ante a infecção por CoronavÃrus. Research, Society and Development, 2021, 10, e49710817355.	0.0	0
28	COVID-19, Acute Lymphoblastic Leukemia, and Down Syndrome: A Short Review and a Case Report. Case Reports in Oncology, 2021, 14, 1031-1039.	0.3	2
29	Second Episode of Multisystem Inflammatory Syndrome in Children. Pediatric Infectious Disease Journal, 2021, 40, e452-e452.	1.1	4
30	Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome. Frontiers in Aging Neuroscience, 2021, 13, 700280.	1.7	11
32	Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3748.	1.0	7
33	The impact of coronavirus disease 2019 (COVID-19) on older adults with an intellectual disability during the first wave of the pandemic in Ireland. HRB Open Research, 2021, 4, 93.	0.3	8
34	Lung disease manifestations in Down Syndrome. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L892-L899.	1.3	11
35	Inflammatory cytokine storms severity may be fueled by interactions of micronuclei and RNA viruses such as COVID-19 virus SARS-CoV-2. A hypothesis. Mutation Research - Reviews in Mutation Research, 2021, 788, 108395.	2.4	8
36	Covid-19 infection in a Down syndrome child. Sudanese Journal of Paediatrics, 2021, 21, 1.	0.6	2
39	Aging with Down Syndromeâ€"Where Are We Now and Where Are We Going?. Journal of Clinical Medicine, 2021, 10, 4687.	1.0	42
40	Treatment of a patient with COVID-19 and adverse premorbid background: A case report. Russian Journal of Pediatric Surgery Anesthesia and Intensive Care, 2021, 11, 395-402.	0.1	0
41	Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence. Journal of Inflammation Research, 2021, Volume 14, 5187-5200.	1.6	15

#	Article	IF	Citations
42	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. Journal of Clinical Medicine, 2021, 10, 5125.	1.0	24
43	Multiple Organ Failure Associated with SARS-CoV-2 Infection in a Child with Down Syndrome: Is Trisomy 21 Associated with an Unfavourable Clinical Course?. Case Reports in Pediatrics, 2021, 2021, 1-4.	0.2	5
45	A phenotypic approach to understanding obesity in children and youth with Down syndrome. International Review of Research in Developmental Disabilities, 2021, , 75-112.	0.6	0
46	Trisomy 21 as a Risk Factor for Severe Illness in COVID-19: Report of two Cases. Tanaffos, 2020, 19, 413-417.	0.5	1
47	Differential microRNA expression profile in blood of children with Down syndrome suggests a role in immunological dysfunction. Human Cell, 2022, 35, 639-648.	1.2	2
49	Treating COVID-19: Evolving approaches to evidence in a pandemic. Cell Reports Medicine, 2022, 3, 100533.	3.3	7
50	ORF8 and Health Complications of COVID-19 in Down Syndrome Patients. Frontiers in Genetics, 2022, 13, 830426.	1.1	1
51	Impact of the COVID-19 pandemic on daily life, mood, and behavior of adults with Down syndrome. Disability and Health Journal, 2022, 15, 101278.	1.6	12
52	Different Course of SARS-CoV-2 Infection in Two Adolescents With Other Immunosuppressive Factors. Cureus, 2022, 14, e22710.	0.2	1
53	COVIDâ€19: A systematic review and update on prevention, diagnosis, and treatment. MedComm, 2022, 3, e115.	3.1	30
54	Reprogramming of red blood cell metabolism in Zika virus–infected donors. Transfusion, 2022, 62, 1045-1064.	0.8	5
55	COVID-19 in an Adult with Down Syndrome: Impact on Autoimmune Response. Case Reports in Infectious Diseases, 2022, 2022, 1-5.	0.2	0
57	SARS-CoV-2 vaccine humoral response in adults with Down syndrome. Clinical Microbiology and Infection, 2022, 28, 1155.e1-1155.e4.	2.8	3
58	Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome. Neuron, 2022, 110, 2063-2079.	3.8	8
59	Defective Immune Response to SARS-CoV-2 Immunization in Down Syndrome Correlates With Increased Susceptibility to Severe Illness With Infection. Journal of Infectious Diseases, 2022, 226, 755-756.	1.9	1
60	Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil. Human Genetics, 2022, 141, 1887-1904.	1.8	5
61	Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination. Clinical Infectious Diseases, 2023, 76, e155-e162.	2.9	6
63	PDGFR kinase inhibitor protects against septic death via regulation of BTLA. Science China Life Sciences, 0, , .	2.3	0

#	Article	IF	CITATIONS
65	Possible factors contributing to chromosomal nondisjunction and formation of trisomic HSA21., 2022, , $59-69$.		0
66	COVIDâ \in 19 hospitalization with later long COVID in a person with Down syndrome. Clinical Case Reports (discontinued), 2022, 10, .	0.2	1
67	Down Syndrome outreach during the COVID-19 pandemic – An interprofessional Zoom® WhatsApp® collaboration in Syria. Journal of Pediatric Health Care, 2022, , .	0.6	0
68	A global mental health opportunity: How can cultural concepts of distress broaden the construct of immobility?. Global Environmental Change, 2022, 77, 102594.	3.6	6
69	Expert-opinion-based guidance for the care of children with lysosomal storage diseases during the COVID-19 pandemic: An experience-based Turkey perspective. Frontiers in Public Health, $0,11,11$	1.3	0
70	A Comprehensive Mini-review on COVID-19 Pathogenesis on Perspectives of Cytokine Storm and Recent Developments in Anti-Covid Nucleotide Analogues. Journal of Pure and Applied Microbiology, 2023, 17, 1-11.	0.3	O
71	HIV and Associated Indicators of COVID-19 Cytokine Release Syndrome: A Meta-Analysis and Meta-Regression. Cureus, 2023, , .	0.2	0
72	4-Hydroxynonenal Is Linked to Sleep and Cognitive Disturbances in Children: Once upon the Time of COVID-19., 0, , .		0
73	Medication Adherence in Children with Down Syndrome with Autoimmune Thyroid Disease During the COVID-19 Pandemic: Indonesian Study. Journal of Comprehensive Pediatrics, 2023, 14, .	0.1	0
74	All-cause and cause-specific mortality among people with and without intellectual disabilities during the COVID-19 pandemic in the Netherlands: a population-based cohort study. Lancet Public Health, The, 2023, 8, e356-e363.	4.7	10